Who is sponsoring NCT03123445?

NCT03123445 is sponsored by China Medical University, China.

What condition does NCT03123445 study?

NCT03123445 studies Non Small Cell Lung Cancer.

What drugs are being tested in NCT03123445?

Interventions: Endostar, Gemcitabine, Cisplatin.

What is the status of NCT03123445?

NCT03123445 is currently UNKNOWN.

Last reviewed 2017-04-18 · How we verify

The Efficacy and Safety of Continuous Administration of Endostar Combined With Chemotherapy for Patients With Advanced no Small Cell Lung Cancer: An Open-label, no Randomized Controlled Multicenter Phase II Study

NCT03123445 Phase 2 UNKNOWN

Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection pump combined GP（gemcitabine+cisplatin） scheme for first-line advanced non small cell lung cancer and maintenance treatment.

Details

Lead sponsor	China Medical University, China
Phase	Phase 2
Status	UNKNOWN
Enrolment	150
Start date	2017-04
Completion	2019-09

Conditions

Non Small Cell Lung Cancer

Interventions

Endostar
Gemcitabine
Cisplatin

Primary outcomes

Progression-free Survival (PFS) — Time Frame: up to month 36
PFS is a tumor progression or death time of a patient who has an objective record on the date of enrollment. PFS calculation end if the patient was lost, unknown death , or other anti tumor therapy was used.